TrialCellular oncology (Dordrecht, Netherlands)2025

Surufatinib plus paclitaxel as second-line therapy for advanced gastric cancer: a single-arm, phase 2 clinical trial.

Ting Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.